Striatal and extra-striatal D2/D3 dopamine receptor occupancy by quetiapine in vivo -: [123I]-epidepride single photon emission tomography (SPET) study

被引：62

作者：

Stephenson, CME

Bigliani, V

Jones, HM

Mulligan, RS

Acton, PD

Visvikis, D

Ell, PJ

Kerwin, RW

Pilowsky, LS

机构：

[1] Inst Psychiat, Dept Psychol Med, Sect Neurochem Imaging, London SE5 8AF, England

[2] UCL, Middlesex Hosp, Sch Med, Inst Nucl Med, London, England

[3] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA

来源：

BRITISH JOURNAL OF PSYCHIATRY | 2000年 / 177卷

关键词：

D O I：

10.1192/bjp.177.5.408

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Background Selective action at limbic cortical dopamine D-2-like receptors could mediate atypical antipsychotic efficacy with few extrapyramidal side-effects. Aims To test-the hypothesis that quetiapine has 'limbic selective' D-2/D-3 receptor occupancy in vivo. Method The high-affinity D-2/D-3 ligand [I-123]-epidepride and single photon emission tomography were used to estimate D-2/D-3 specific binding and an index of relative percentage D-2/D-3 occupancy in striatal and temporal cortical regions for quetiapine-treated patients (n=6). Quetiapine-, and previously studied typical-antipsychotic- and clozapine-treated patients were compared. Results Mean (s.d) relative percentage D-2/D-3 receptor occupancy by quetiapine was 32.0% (14.6) in striatum and 60.1% (17.2) in temporal cortex (mean daily dose 450 mg: range 300-700 mg/day). Quetiapine treatment resulted in limbic selective D-2/D-3 blockade similar to clozapine and significantly higher than typical antipsychotics. Conclusions Preliminary data suggest that limbic selective D-2/D-3 receptor blockade is important for atypical drug action. Declaration of interest C.M.E.S. and H.M.J. were supported by research grants from AstraZeneca, V.B. by a research grant from Eli Lilly and R.S.M. by a UK Medical Research Council (MRC) Senior Clinical Research Fellowship Award. LS.P. is a UK MRC Senior Clinical Research Fellow.

引用

页码：408 / 415

页数：8

共 35 条

[1]

Abi-Dargham A, 1999, SCHIZOPHR RES, V36, P239

[2]

*ALC DRUG AB MENT, 1974, ABN INV MOV SCAL AIM

[3]

ANDREASON NC, 1981, SCALE ASSESSMENT NEG

[4]

ANDREASON NC, 1984, SCALE ASSESSMENT POS

[5] Multiple fixed doses of ''Seroquel'' (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo [J].

Arvanitis, LA ;

Miller, BG ;

Borison, RL ;

Pitts, WM ;

Sharif, ZA ;

Hamner, MB ;

Herz, MI ;

True, JE ;

Velligan, D ;

Knesevich, MA ;

Small, J ;

Steinbook, R ;

Hertzman, M ;

Keck, PE ;

Newcomer, JW ;

Grace, J ;

Rotrosen, J ;

Tandon, R ;

Dott, SG ;

Ferguson, JM ;

Addington, DEN ;

MacEwan, GW ;

Nair, VNP ;

Shriqui, CL ;

Williams, R ;

Daniel, DG ;

Shehi, GM ;

Patterson, WM ;

Merideth, CH .

BIOLOGICAL PSYCHIATRY, 1997, 42 (04) :233-246

[6] A RATING-SCALE FOR DRUG-INDUCED AKATHISIA [J].

BARNES, TRE .

BRITISH JOURNAL OF PSYCHIATRY, 1989, 154 :672-676

[7] In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs -: [123I]-epidepride single photon emission tomography (SPET) study [J].

Bigliani, V ;

Mulligan, RS ;

Acton, PD ;

Visvikis, D ;

Ell, PJ ;

Stephenson, C ;

Kerwin, RW ;

Pilowsky, LS .

BRITISH JOURNAL OF PSYCHIATRY, 1999, 175 :231-238

[8] DOPAMINE-RECEPTORS IN HUMAN-BRAIN - AUTORADIOGRAPHIC DISTRIBUTION OF D2 SITES [J].

CAMPS, M ;

CORTES, R ;

GUEYE, B ;

PROBST, A ;

PALACIOS, JM .

NEUROSCIENCE, 1989, 28 (02) :275-290

[9]

Damasio H., 1989, Lesion analysis in neuropsychology

[10]

ENDICOTT J, 1976, ARCH GEN PSYCHIAT, V33, P766

← 1 2 3 4 →